You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Antimicrobial susceptibility ofNeisseria gonorrhoeaeisolates (n=193) from Belarus, 2010–2013

From: Antimicrobial susceptibility/resistance and NG-MAST characterisation of Neisseria gonorrhoeae in Belarus, Eastern Europe, 2010–2013

Antimicrobial MIC50/ Susceptible (%) Intermediate susceptible (%) Resistant (%)
MIC90/ 2010-2011 2012 2013 2010-2011 2012 2013 2010-2011 2012 2013
MIC range (n=78)a (n=75) (n=40) (n=78)a (n=75) (n=40) (n=78)a (n=75) (n=40)
(mg/L)
Penicillin Gb 0.032/1/ - 88 78 - 5 10 - 7 13
0.008-2
Ceftriaxoneb 0.008/0.047/ 100 100 100 NA NA NA 0 0 0
<0.002-0.125
Cefiximeb 0.023/0.047/ 100 100 97.5 NA NA NA 0 0 2.5
<0.016-0.25
Azithromycinb 0.19/0.38/ 65 83.3 90 23 15.3 10 12 1.3 0
0.032-1
Ciprofloxacinb 0.006/6/ 64 79 72 1 0 0 35 21 28
0.003- >32
Tetracyclineb 0.38/24/ 56 56 55 8 9 5 36 35 40
0.094-24
Spectinomycinb 12/16/3-16 100 100 100 NA NA NA 0 0 0
Gentamicinc 2010-2011: 2012: 2013:
MIC range: 0.25-16 mg/L; MIC50: 2 mg/L; MIC90: 4 mg/L MIC range: 2-16 mg/L; MIC50: 4 mg/L; MIC90: 8 mg/L MIC range: 3-12 mg/L; MIC50: 6 mg/L; MIC90: 8 mg/L
  1. MIC50, minimum inhibitory concentration of 50% of isolates; MIC90, minimum inhibitory concentration of 90% of isolates; −, Not tested; NA, not applicable.
  2. aDue to the few isolates obtained in 2011, isolates from 2010 (n=72) and 2011 (n=6) were evaluated as one time point.
  3. bBreakpoints for susceptible and resistant isolates were according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.eucast.org/clinical_breakpoints).
  4. cBreakpoints not stated by any organization.